RecruitingPhase 2NCT06730347
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Studying Adenocarcinoma of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- MacroGenics
- Principal Investigator
- Pepi PenchevaMacroGenics
- Intervention
- Lorigerlimab(biological)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2025 – 2027
Study locations (16)
- UCLA, Los Angeles, California, United States
- Ochsner MD Anderson Cancer Center, New Orleans, Louisiana, United States
- START Midwest, Grand Rapids, Michigan, United States
- West Penn Allegheny Health, Pittsburgh, Pennsylvania, United States
- Mays Clinic, Houston, Texas, United States
- START San Antonio, San Antonio, Texas, United States
- Wisconsin Institute Medical Research- UW Cancer Connect, Madison, Wisconsin, United States
- Princess Margaret Cancer Center, Toronto, Ontario, Canada
- McGill University, Montreal, Quebec, Canada
- National Cancer Center, Goyang-si, Gyeonggi-do, South Korea
- Seoul National University Hospital Bundang Hospital, Seongnam-si, Gyeonnggi-Do, South Korea
- Yonsei University Health System Severance Hospital, Seoul, South Korea
- Gangnam Severance Hospital, Seoul, South Korea
- Korea University Guro Hospital, Seoul, South Korea
- Seoul National University Hospital, Seoul, South Korea
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06730347 on ClinicalTrials.govOther trials for Adenocarcinoma of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07523529Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsBeijing Biotech
- RECRUITINGNCT07100288Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian CancerComplejo Hospitalario Universitario Insular Materno Infantil
- RECRUITINGPHASE1NCT06840886A Study of PHST001 in Advanced Solid TumorsPheast Therapeutics
- RECRUITINGPHASE2NCT05500391Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringCentre Oscar Lambret
- RECRUITINGPHASE1, PHASE2NCT05922930Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic CancerM.D. Anderson Cancer Center
- RECRUITINGPHASE3NCT05601700Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)Ente Ospedaliero Ospedali Galliera
- ACTIVE NOT RECRUITINGPHASE2NCT05335993A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.CanariaBio Inc.
- RECRUITINGNCT03452774SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryMassive Bio, Inc.